|Molecular Weight||Approximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 152 amino acids.|
|AA Sequence||重組馬白介素-1受體拮抗劑蛋白蛋白HPLGKRPCKM QAFRIWDVNQ KTFYMRNNQL VAGYLQESNT KLQEKIDVVP IEPDALFLGL HGRKLCLACV KSGDEIRFQL EAVNITDLSK NKEENKRFTF IRSNSGPTTS FESAACPGWF LCTAQEADRP VSLTNKPKES FMVTKFYLQE DQ|
|Purity||> 95 % by SDS-PAGE and HPLC analyses.|
|Biological Activity||Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-1α-dependent proliferation of murine D10S cells is less than 3.0 μg/ml, corresponding to a specific activity of > 333 IU/mg in the presence of 50 pg/ml rHuIL-1α.|
|Physical Appearance||重組馬白介素-1受體拮抗劑蛋白蛋白Sterile Filtered White lyophilized (freeze-dried) powder.|
|Formulation||Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.|
|Endotoxin||Less than 1 EU/μg of rEqIL-1RA as determined by LAL method.|
|Reconstitution||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.|
|Storage||This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.|
1. Dinarello CA. 1994. FASEB J. 8:1314-25.
2. Patterson D, Jones C, Hart I, et al. 1993. Genomics. 15:173-6.
3. Steinkasserer A, Spurr NK, Cox S, et al. 1992. Genomics. 13:654-7.
4. Perrier S, Darakhshan F, Hajduch E. 2006. FEBS Lett. 580:6289-94.
5. Gabay C, Porter B, Fantuzzi G, et al. 1997. J Immunol. 159:5905-13.
|Background||IL-1RA was initially called the IL-1 inhibitor which is encoded by the IL1RN gene and it is a member of the interleukin 1 cytokine family. It is secreted by various types of cells including immune cells, epithelial cells, and adipocytes. IL-1RA has functions of inhibiting the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. IL-1RA is also used in the treatment of rheumatoid arthritis, an autoimmune disease in which IL-1 plays a key role. The equus caballus IL-1RA is a single non-glycosylated polypeptide chain containing 152 amino acids and it has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. The protein shows 26 % amino acid homology to IL-1β and 19 % homology to IL-1α. It also shares 78 %~80 % a.a. sequence identity with murine, rat, porcine IL-1RA.|